Search research articles
Contact Us
Filters
Showing results (51-60 of 96) with videos related to
Page
of 10
Sort By:
JAMA Oncology
|
October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial
Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
Genes, Chromosomes & Cancer
|
October 24, 2018
GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement
Sabrina Croce, Tom Lesluyes, Lucile Delespaul, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 2, 2015
Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions
Sabrina Croce, Agnes Ribeiro, Celine Brulard, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure
Antonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
The Lancet. Healthy Longevity
|
September 13, 2022
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study
Claire Falandry, Fanny Pommeret, Laurence Gladieff, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 96) with videos related to
Sort By:
Page
of 10
JAMA Oncology
|
October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial
Isabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
The Lancet. Oncology
|
October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
Genes, Chromosomes & Cancer
|
October 24, 2018
GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement
Sabrina Croce, Tom Lesluyes, Lucile Delespaul, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 2, 2015
Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions
Sabrina Croce, Agnes Ribeiro, Celine Brulard, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 11, 2023
Efficacy of chemotherapy according to <i>BRCA</i> status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, et al.
Gynecologic Oncology
|
August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
Nicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine
|
October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 22, 2010
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure
Antonin Schmitt, Laurence Gladieff, Céline M Laffont, et al.
The Lancet. Healthy Longevity
|
September 13, 2022
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study
Claire Falandry, Fanny Pommeret, Laurence Gladieff, et al.
Page
of 10